Adveq

Bizongo is a tech-enabled B2B e-commerce and supply chain platform specializing in customized goods, including packaging, textiles, and apparel. Founded in 2015 by three IIT graduates, the company aims to digitize the fragmented B2B segment of made-to-order products. Bizongo offers a comprehensive suite of services such as digital vendor management, supply chain automation, and supply chain financing. Its platform connects businesses with a network of over 1,500 curated manufacturers, addressing key challenges like inventory management and operational efficiency. Through its innovative approach, Bizongo seeks to streamline the supply chain process, reduce costs, and facilitate easier contract management for its clients.

Lenskart is an innovative online optical store in India that offers a wide range of eyewear, including prescription glasses, branded contact lenses, sunglasses, and accessories. Customers can choose from over 500 designs of eyeglass frames, with prices ranging from Rs. 399 to Rs. 4,000. The platform provides a user-friendly experience, allowing customers to select a frame, input their prescription details, and place an order easily. Lenskart ensures a hassle-free shopping experience with a 48-hour free home delivery guarantee and a 365-day return policy. Additionally, it boasts a comprehensive collection of discounted contact lenses from top brands, catering to various needs, including disposable, toric, colored, and bifocal options. By focusing on convenience and affordability, Lenskart aims to transform the eyewear shopping experience for its customers.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Bizongo is a tech-enabled B2B e-commerce and supply chain platform specializing in customized goods, including packaging, textiles, and apparel. Founded in 2015 by three IIT graduates, the company aims to digitize the fragmented B2B segment of made-to-order products. Bizongo offers a comprehensive suite of services such as digital vendor management, supply chain automation, and supply chain financing. Its platform connects businesses with a network of over 1,500 curated manufacturers, addressing key challenges like inventory management and operational efficiency. Through its innovative approach, Bizongo seeks to streamline the supply chain process, reduce costs, and facilitate easier contract management for its clients.

LEAP India is a supply chain solutions company that specializes in providing comprehensive logistics and inventory management services. The company operates an online platform designed to facilitate supply chain management, focusing on returnable packaging and equipment pooling. This includes a range of materials such as wooden pallets, plastic containers, wooden boxes, and metal wire mesh, which are essential for various sectors in the storage and transfer of products. By addressing the logistics challenges faced by fast-moving consumer goods companies, LEAP India aims to enhance efficiency in supply chain operations and support businesses in meeting their logistical needs.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

Tessian Limited is a company that specializes in email security software designed to mitigate risks associated with human error and data loss. Founded in 2013 and headquartered in London, the company offers advanced solutions that leverage machine learning and artificial intelligence. Key products include CheckRecipient Guardian, which alerts users in real-time if emails are being sent to unintended recipients, and CheckRecipient RuleBuilder, which allows organizations to easily create and enforce email communication policies. The platform analyzes email networks to prevent sensitive information from being misdirected, thereby protecting clients in various sectors, including legal services, healthcare, investment banking, and technology. Tessian aims to enhance security while ensuring minimal disruption to employees' workflows, empowering them to work efficiently without compromising data integrity.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

HAYA Therapeutics is a company focused on developing RNA-based therapeutics aimed at treating heart failure and other fibrotic diseases. The company specializes in biopharmaceutical therapies that target specific regulators of fibrosis, particularly long noncoding RNA, which plays a critical role in myocardial fibrosis. By honing in on heart-specific mechanisms, HAYA Therapeutics seeks to enhance the efficacy and safety of treatments for heart-related illnesses and other serious conditions associated with aging, including cancer. Through its innovative approach, the company aims to improve patient outcomes in the management of heart failure and related health challenges.

Bizongo is a tech-enabled B2B e-commerce and supply chain platform specializing in customized goods, including packaging, textiles, and apparel. Founded in 2015 by three IIT graduates, the company aims to digitize the fragmented B2B segment of made-to-order products. Bizongo offers a comprehensive suite of services such as digital vendor management, supply chain automation, and supply chain financing. Its platform connects businesses with a network of over 1,500 curated manufacturers, addressing key challenges like inventory management and operational efficiency. Through its innovative approach, Bizongo seeks to streamline the supply chain process, reduce costs, and facilitate easier contract management for its clients.

Synendos Therapeutics AG is a biopharmaceutical company based in Allschwil, Switzerland, founded in 2019. It specializes in developing therapies for neuropsychiatric disorders, particularly focusing on anxiety, mood, and stress-related conditions. The company is pioneering a new class of small molecules that target the endocannabinoid system to restore natural brain function. By modulating cannabinoid activity and inhibiting endocannabinoid transport across cell membranes, Synendos aims to rebalance altered neurotransmission in various areas of the brain. This innovative approach addresses significant unmet medical needs, particularly for conditions such as post-traumatic stress disorder (PTSD), where there is a high demand for effective pharmacological treatments.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Cedilla Therapeutics, Inc. is a biotechnology company focused on developing targeted small-molecule therapeutics for cancer and diseases linked to protein dysregulation. The company employs innovative strategies to destabilize oncoprotein targets, utilizing methods such as direct ligand-induced degradation, disruption of stabilizing protein-protein interactions, and the identification of upstream regulators that affect protein stability. Cedilla's comprehensive approach also includes large-scale proteomic analyses to map protein susceptibility, enhancing the potential for effective therapies. By concentrating on the transitions between stable and susceptible protein states, Cedilla aims to create novel treatments that broaden the applicability of small molecule therapeutics beyond oncology. Founded in 2017 and headquartered in Cambridge, Massachusetts, the company was formerly known as Protein Stability Newco, Inc. before rebranding in 2018.

Casma Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing innovative therapeutic strategies centered on the natural cellular process of autophagy. Founded in 2017, the company aims to enhance autophagy to improve the clearance of unwanted proteins, organelles, and pathogens, thereby addressing significant medical challenges. Casma Therapeutics is advancing preclinical programs targeting various conditions, including muscle disorders, liver disease, inflammatory disorders, and neurodegenerative diseases. By harnessing and manipulating the autophagy system, the company seeks to arrest or reverse disease progression, ultimately enabling physicians to meet unmet medical needs and provide effective treatments for patients with serious health issues.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

MISSION Therapeutics is a biotechnology company specializing in developing drugs that target the cellular process of deubiquitylation for the treatment of cancer and other diseases. Their focus is on developing small molecule drugs that selectively inhibit specific deubiquitylating enzymes (DUBs), which play crucial roles in regulating protein degradation and cellular processes. These drugs aim to intervene in disease mechanisms where DUB dysregulation is implicated, offering potential therapeutic benefits.

Goldfinch Bio, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, dedicated to discovering and developing precision therapies for patients with kidney diseases. The company focuses on conditions such as focal segmental glomerulosclerosis, diabetic nephropathy, and polycystic kidney disease. Key product candidates include GFB-887, a selective inhibitor of the TRPC5 channel, and GFB-024, a cannabinoid receptor 1 inverse agonist. Goldfinch Bio integrates advancements in kidney genetics and biology through its Kidney Genome Atlas, a genomic registry that aids in identifying new disease targets and biomarkers. Additionally, the company employs stem cell science to create human organoid models, which facilitate the validation of novel therapeutic targets. Goldfinch Bio has established a strategic collaboration with Gilead Sciences to further enhance its research and development efforts. Founded in 2016, Goldfinch Bio aims to transform the treatment landscape for progressive kidney disease.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative therapies for fibrotic diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both indications and is currently undergoing Phase 2a clinical trials. The company is also developing PLN-1474, a small-molecule selective inhibitor of avß1, for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 trials. Founded in 2015, Pliant Therapeutics is also advancing preclinical programs aimed at addressing oncology and muscular dystrophies.

Bizongo is a tech-enabled B2B e-commerce and supply chain platform specializing in customized goods, including packaging, textiles, and apparel. Founded in 2015 by three IIT graduates, the company aims to digitize the fragmented B2B segment of made-to-order products. Bizongo offers a comprehensive suite of services such as digital vendor management, supply chain automation, and supply chain financing. Its platform connects businesses with a network of over 1,500 curated manufacturers, addressing key challenges like inventory management and operational efficiency. Through its innovative approach, Bizongo seeks to streamline the supply chain process, reduce costs, and facilitate easier contract management for its clients.

iOnctura is a biopharmaceutical company specializing in the development of novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which plays a significant role in cancer progression. The company seeks to enhance existing immune checkpoint therapies by creating new drugs that, when used in conjunction with these therapies, may improve safety and efficacy for cancer patients. iOnctura has formed strategic partnerships with prominent organizations, including Merck and Cancer Research Technology, to advance a pipeline of preclinical molecules toward clinical application. With access to advanced drug discovery labs and a network of academic collaborators, iOnctura is well-equipped to develop innovative combination therapies in the realm of cancer immunology, ultimately striving to optimize treatment outcomes for patients.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.

Araris Biotech AG is a biotechnology start-up based in Zurich, Switzerland, founded in 2019. The company specializes in developing antibody-drug conjugate (ADC) linker technology aimed at enhancing chemotherapy by delivering chemotherapeutic agents directly to targeted antibodies. This innovative platform allows for the rapid production of high-quality ADCs without the need for extensive engineering of antibodies or cell lines, enabling the use of readily available antibodies. The site-specific conjugation process facilitates swift manufacturing and reliable quality control, supporting the creation of safe and potent drugs for various diseases. Araris Biotech's technology is protected by two patents, underscoring its commitment to advancing cancer treatment through improved safety and tolerability for patients.

Revolution Medicines is a clinical-stage precision oncology company dedicated to developing novel targeted therapies for cancer treatment. Founded by Martin D. Burke, the company leverages an innovative approach to synthesize complex natural products into optimized drug candidates. This method involves rapidly assembling simple chemical building blocks into refined structures with significant therapeutic potential. Revolution Medicines focuses on inhibiting elusive targets within key growth and survival pathways, particularly RAS and mTOR signaling pathways. The company's portfolio includes therapies like RMC-4630, a SHP2 inhibitor, as well as programs targeting SOS1 and 4EBP1/mTORC1.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, specializing in the development of innovative therapies for advanced liver diseases and cancers associated with Claudin-1 (CLDN1) expression. Founded in 2019, Alentis focuses on addressing conditions such as liver fibrosis, cirrhosis, and liver cancer through the use of anti-CLDN1 antibody-drug conjugates and other targeted treatments. The company's unique approach combines clinically relevant read-outs with advanced techniques like single-cell RNA sequencing of patient liver tissues, aiming to reverse disease progression and improve patient outcomes. Alentis Therapeutics is recognized for its pioneering role in exploring anti-CLDN1 therapeutics, contributing to advancements in the treatment of fibrotic diseases and CLDN1-positive tumors.

ECheng (e成) is a B2B SaaS platform that provides HR matching and resume screening for enterprises. Using machine learning, data mining, and NLP (natural language processing), the company categorizes resumes that best fit the job requirements of the client company. The company was launched in 2013 by industry veterans from Baidu, IBM, and Microsoft, serving multinational conglomerates as well as small and medium-sized companies.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

ImmunOs Therapeutics AG is a clinical-stage biotechnology company based in Schlieren, Switzerland, founded in 2014. The company specializes in the discovery and development of innovative immunotherapies aimed at enhancing cancer treatment and addressing autoimmune diseases. ImmunOs focuses on creating novel human immunomodulatory proteins that play a role in both innate and adaptive immunity. Their therapeutics are designed to exert direct anti-tumor effects by remodeling the tumor microenvironment, while also developing antibodies that inhibit the activation of specific HLA molecules linked to autoimmune conditions. Through its research and development efforts, ImmunOs aims to improve the lives of patients facing serious diseases.

Pliant Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, dedicated to discovering and developing innovative therapies for fibrotic diseases. Its lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both indications and is currently undergoing Phase 2a clinical trials. The company is also developing PLN-1474, a small-molecule selective inhibitor of avß1, for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, which is in Phase 1 trials. Founded in 2015, Pliant Therapeutics is also advancing preclinical programs aimed at addressing oncology and muscular dystrophies.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

Decibel Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing innovative therapies aimed at protecting, repairing, and restoring hearing. The company addresses various hearing disorders, including those related to pediatric cancers, cystic fibrosis, noise exposure, age-related and genetic hearing loss, as well as conditions characterized by persistent tinnitus. Decibel Therapeutics employs a multifaceted approach that includes drug delivery to the inner ear, advanced imaging techniques, and pharmacokinetic and pharmacodynamic modeling. The company leverages its expertise in inner ear biology, single-cell genomics, and bioinformatics to develop effective treatments for hearing loss and related disorders. Established in 2013 and headquartered in Boston, Massachusetts, Decibel Therapeutics was originally known as Hearing, Inc. before rebranding in 2014.

Memo Therapeutics AG is a Swiss biotechnology company based in Basel, specializing in antibody discovery and immune repertoire analysis. The company has developed the MemoMAB platform, which generates a recombinant in vitro copy of an individual’s B cell or antibody repertoire, creating a comprehensive library of unique antibodies. This innovative technology allows for the identification of a vast array of relevant and rare antibodies, significantly enhancing the potential for immune repertoire analysis and antibody discovery. Memo Therapeutics aims to leverage its platform in proprietary antibody lead discovery programs and through collaborations, with a focus on improving treatment options for patients suffering from viral infections and cancer.

Revolution Medicines is a clinical-stage precision oncology company dedicated to developing novel targeted therapies for cancer treatment. Founded by Martin D. Burke, the company leverages an innovative approach to synthesize complex natural products into optimized drug candidates. This method involves rapidly assembling simple chemical building blocks into refined structures with significant therapeutic potential. Revolution Medicines focuses on inhibiting elusive targets within key growth and survival pathways, particularly RAS and mTOR signaling pathways. The company's portfolio includes therapies like RMC-4630, a SHP2 inhibitor, as well as programs targeting SOS1 and 4EBP1/mTORC1.

Amal Therapeutics SA, established in 2012 in Geneva, Switzerland, is a biotechnology company focused on developing therapeutic vaccines for oncology. It utilizes its proprietary cell penetrating peptide platform to create and advance cancer vaccines designed to stimulate the immune system's cellular response against tumors. As of mid-2019, Amal Therapeutics operates as a subsidiary of Boehringer Ingelheim GmbH.

Rethink Robotics is a Boston-based company that develops industrial robots aimed at enhancing automation in the manufacturing sector. Its flagship robot, Baxter, utilizes the advanced Intera software platform to assist manufacturers in various industries, including automotive, electronics, and consumer goods. By providing a safe, trainable, and cost-effective workforce solution, Rethink Robotics enables organizations to optimize labor, increase operational flexibility, and reduce costs. The company's robots are designed to handle various tasks, such as loading and unloading, packing, and machining, effectively automating dull, dangerous, and dirty jobs. Additionally, Rethink Robotics offers the Baxter Research Robot, a humanoid platform equipped with integrated sensors and an open software development kit, facilitating research and development in both academic and corporate environments.

Aevi is a FinTech company focused on creating a more open payment ecosystem, enabling seamless transactions for users globally. The company operates a cloud-based platform that facilitates the flow of payment and transaction data across various channels and consumer touchpoints, enhancing the in-person payment experience. By connecting digital and physical payment channels, Aevi simplifies the payment infrastructure with an advanced payment gateway compatible with both legacy and modern devices. This allows merchants to manage their businesses effectively while improving customer experiences in-store. With a presence in Europe, Australia, and the United States, Aevi has established offices in London, Prague, and Paderborn, furthering its mission to liberate payment processes and provide comprehensive analytics for informed decision-making.

FirstCry is an online platform based in Pune, India, specializing in baby and kids' products. Founded in 2010, the company offers an extensive range of over 20,000 items from more than 250 renowned international and Indian brands, including Mattel, Pampers, and Disney. FirstCry's business model encompasses not only the sale of baby products and toys but also the wholesale distribution of fast-moving consumer goods (FMCG) through various partners. Additionally, the company operates a preschool segment via franchise partnerships across India. By focusing on quality products and providing a reliable online shopping experience, FirstCry aims to ensure customer satisfaction through prompt delivery services and responsive customer care.

Lenskart is an innovative online optical store in India that offers a wide range of eyewear, including prescription glasses, branded contact lenses, sunglasses, and accessories. Customers can choose from over 500 designs of eyeglass frames, with prices ranging from Rs. 399 to Rs. 4,000. The platform provides a user-friendly experience, allowing customers to select a frame, input their prescription details, and place an order easily. Lenskart ensures a hassle-free shopping experience with a 48-hour free home delivery guarantee and a 365-day return policy. Additionally, it boasts a comprehensive collection of discounted contact lenses from top brands, catering to various needs, including disposable, toric, colored, and bifocal options. By focusing on convenience and affordability, Lenskart aims to transform the eyewear shopping experience for its customers.

Airborne International is engaged in engineering, manufacturing, and supplying high-end composites structures for industries such as aerospace, defense, marine, high-end bicycles, and formula-one cars. It offers composites structures maintenance and repair services, including inspection and damage assessment, sealing and painting, and balancing. The company was founded in 1995 and is based in The Hague, the Netherlands.

Secured Mail, established in 2006 by managing director Mark Bigley, is a licensed postal operator in the United Kingdom that specializes in e-commerce, bulk mail, and retail logistics. It has rapidly ascended to become the third leading player in the wholesale Downstream Access (DSA) market, allowing it to efficiently utilize Royal Mail’s Mail Centre network. By collecting mail directly from customers' production facilities, Secured Mail transports it to its own hubs for sorting before nationwide delivery using its own fleet. The company contracts Royal Mail for the final delivery to customers' mailboxes the following day. Secured Mail serves a diverse client base, including prominent companies such as Amazon, Domino’s Pizza, and Centrica, the owner of British Gas.